Kualitas bukti 4.5/5
Skor tinjauan delapan dimensi terhadap rubrik kualitas . Setiap dimensi dinilai 1–5.
- D1 Dasar sumber
- 4/5
- D2 Otoritas sumber
- 4/5
- D3 Aritmetika
- 5/5
- D4 Ketidakpastian
- 4/5
- D5 Cakupan
- 5/5
- D6 Prosa
- 5/5
- D7 Kejujuran persepsi
- 4/5
- D8 Kelengkapan peringatan
- 5/5
● faktor Anda — klik risiko ini ▾ untuk menampilkan
- Faktor Anda
≈ Sama mungkinnya dengan
Dipersepsikan
Kanker ovarium menempati ruang yang tidak proporsional dalam lanskap ketakutan publik relatif terhadap insidennya yang sebenarnya — sebagian karena sering didiagnosis terlambat, sebagian karena kisah deteksi dini jauh kurang meyakinkan dibanding kanker payudara atau serviks. Tidak ada tes skrining tingkat populasi yang andal, dan pembingkaian «pembunuh senyap» dalam liputan media memperkuat kesan bahwa penyakit ini menyerang tanpa peringatan. Sebagian besar wanita tidak dapat membedakan antara risiko seumur hidup kanker ovarium (~1 %) dan risiko seumur hidup kanker payudara (~13 %), dan keduanya sering disamakan dalam percakapan santai tentang «kanker wanita».
Perkiraan kasar: Banyak orang dewasa mengira kanker ovarium hampir sama umum dengan kanker payudara
Sumber: intuisi redaksi, bukan hasil survei
Aktual
~1 dari 91 wanita AS risiko diagnosis seumur hidup
Wanita AS, semua usia
Tampilkan perhitungan
American Cancer Society memperkirakan risiko seumur hidup seorang wanita AS untuk mengembangkan kanker ovarium sekitar 1 dari 91 (~1,1 %), berdasarkan data insiden SEER. SEER mengonfirmasi sekitar 1,1 % wanita akan didiagnosis kanker ovarium pada suatu saat selama hidupnya, berdasarkan data 2021-2023. ACS memproyeksikan ~21.010 kasus baru dan ~12.450 kematian pada 2026. Risiko seumur hidup meninggal akibat kanker ovarium lebih rendah, sekitar 1 dari 143 (~0,7 %), karena kira-kira 50 % kasus kini bertahan hidup. Estimasi titik 0,011 untuk insiden; pita ketidakpastian mencerminkan rentang antara angka kematian-saja (~0,007) dan estimasi insiden historis yang lebih tua dan lebih tinggi (~0,013) sebelum penurunan sekuler yang didorong oleh penggunaan kontrasepsi oral dan berkurangnya terapi hormon.
Catatan: Entri ini adalah *insiden* seumur hidup (diagnosis), bukan mortalitas. Laju fata…
Entri ini adalah *insiden* seumur hidup (diagnosis), bukan mortalitas. Laju fatalitas kasus kanker ovarium tinggi dibandingkan kanker ginekologis lainnya — kira-kira 60 % wanita yang didiagnosis pada akhirnya akan meninggal akibat penyakit ini — karena tidak ada tes skrining populasi yang efektif dan sebagian besar kasus didiagnosis pada stadium lanjut. Label «pembunuh senyap» sebagian layak: gejala tahap awal tidak spesifik dan mudah dikaitkan dengan penyebab lain. Namun, risiko dasar seumur hidup mengembangkan kanker ovarium (~1 dari 91) kira-kira 12x lebih rendah daripada angka setara untuk kanker payudara (~1 dari 8), suatu selisih yang tidak disadari banyak orang.
Bagaimana risiko bervariasi
Angka utama merata-ratakan situasi yang sangat berbeda. Berikut bagaimana probabilitas bervariasi berdasarkan skenario atau konteks:
1 dari 91 · 1,1%
ACS/SEER: ~1 in 91 lifetime incidence
1 dari 83 · 1,2%
Slightly higher age-adjusted incidence than Black women
1 dari 111
Lower incidence but higher case-fatality and later-stage diagnosis on average
Panjang dan gradasi warna batang memeringkat skenario ini satu sama lain, bukan terhadap risiko lain. Peluang pastinya ditampilkan di samping masing-masing.
Risiko terkait
Risiko lain dengan tema serupa — untuk menjelajahi ketakutan terkait.
Melanoma (UV)
Berapa peluang terkena melanoma dari paparan sinar matahari tanpa pelindung secara teratur?
Pilih penantang
The American Cancer Society puts a US woman’s lifetime risk of developing ovarian cancer at about 1 in 91 (~1.1%), based on SEER registry data. That makes it roughly twelve times rarer than breast cancer at diagnosis — a gap most people do not appreciate, because media coverage of “women’s cancers” tends to blur the boundaries between very different diseases. The ACS projects about 21,010 new cases and 12,450 deaths in 2026, and SEER’s five-year relative survival sits at roughly 51%, far below the 92% figure for breast cancer. The difference is almost entirely about stage at detection: there is no PAP-smear equivalent for the ovaries, and most ovarian cancers are caught after they have spread beyond the pelvis.
The “silent killer” label is partly earned and partly misleading. Early-stage ovarian cancer does produce symptoms — bloating, pelvic pain, urinary urgency, early satiety — but those symptoms are nonspecific and overlap heavily with common gastrointestinal and urinary complaints. The consequence is diagnostic delay, not genuine silence. Ovarian cancer incidence has actually declined over the past several decades, driven primarily by wider use of oral contraceptives (which reduce risk by roughly 50% with five or more years of use) and reduced prescribing of menopausal hormone therapy. The rate of ovarian cancer deaths has fallen by about 45% since 1976, with most of that progress concentrated after the mid-2000s.
The sharpest personal risk modifier is genetic. Carriers of a pathogenic BRCA1 variant face a lifetime ovarian cancer risk of roughly 39-44%, compared to the ~1.1% baseline — a multiplier of about 35x. BRCA2 carriers run a lifetime risk of roughly 11-17%. These figures are clinically important but affect a small fraction of the population (roughly 1 in 400-500 women carry a BRCA1/2 pathogenic variant). First-degree family history of ovarian cancer roughly triples baseline risk even without a known gene variant. For the vast majority of women without known genetic risk factors, ovarian cancer remains an uncommon disease with a serious prognosis — the kind of risk that warrants awareness without warranting alarm.
Fakta terkait
Peluang perempuan di AS didiagnosis kanker ovarium sepanjang hidupnya sekitar 1 in 91. Ketakutan lebih besar karena tidak ada skrining yang andal dan sering terlambat terdeteksi, padahal frekuensinya sekitar sepersepuluh kanker payudara, yang sering dikira sama.
Buku besar klaim
Setiap angka di bawah ini adalah apa yang dilaporkan masing-masing sumber, dengan kutipan kata demi kata yang kami andalkan dan bagaimana kami sampai pada angka kami. Klik tautan mana saja untuk memverifikasi langsung.
3/3 sumber diverifikasi secara independen kata demi kata terhadap sumber terkutip
-
[1] American Cancer Society — Key Statistics for Ovarian Cancer Terverifikasi
Key Statistics for Ovarian Cancer- Statistik
Lifetime risk ~1 in 91; ~21,010 new cases and ~12,450 deaths projected for 2026- Kutipan
“"A woman's risk of getting ovarian cancer during her lifetime is about 1 in 91. Her lifetime chance of dying from ovarian cancer is about 1 in 143. [...] The American Cancer Society estimates that in 2026, about 21,010 new cases of ovarian cancer will be diagnosed and 12,450 women will die of ovarian cancer in the United States." ”
- Data sumber dari
- 2026-01-13
- Diakses
- 2026-04-24 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- ACS gives lifetime incidence directly as ~1 in 91 (~1.1%) and lifetime mortality as ~1 in 143 (~0.7%). The headline figure used here is incidence, not mortality, because the question asks about developing ovarian cancer, not dying from it. The ~60% case-fatality implied by the ratio (0.7/1.1) is considerably higher than for breast cancer (~18%), reflecting later-stage diagnosis on average and the absence of an effective screening test.
- Independensi
- ACS derives its lifetime-probability figures from SEER incidence and mortality data (NCI). Treat as partially dependent with the SEER source below.
-
[2] National Cancer Institute / SEER Program — Cancer Stat Facts: Ovarian Cancer Terverifikasi
Cancer Stat Facts: Ovarian Cancer- Statistik
Approximately 1.1% of women will be diagnosed with ovarian cancer at some point during their lifetime- Kutipan
“"Approximately 1.1 percent of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2021–2023 data." ”
- Data sumber dari
- 2025-04-17
- Diakses
- 2026-04-24 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- SEER provides the upstream population-registry data from which ACS derives its headline figures. The 1.1% lifetime risk is consistent with the ACS "1 in 91" figure. Five-year relative survival for ovarian cancer is approximately 51%, far lower than for breast cancer (91.7%), which is why the diagnosis-to-death gap is narrower here.
- Independensi
- SEER is the upstream data source that ACS cites; treat these two as partially dependent. SEER is included as the authoritative primary-pipeline citation.
-
[3] National Cancer Institute — BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet Terverifikasi
BRCA Gene Changes: Cancer Risk and Genetic Testing Fact Sheet- Statistik
Harmful BRCA1/BRCA2 gene changes occur in about 0.2%-0.3% of the general population, roughly 1 in 400- Kutipan
“"The prevalence of harmful BRCA gene changes in the general population is about 0.2%-0.3% (or about 1 in 400)." ”
- Data sumber dari
- 2024-11-19
- Diakses
- 2026-07-03 · salinan arsip
- Verifikasi
- Kutipan diambil ulang secara independen dan dikonfirmasi kata demi kata terhadap sumber terkutip selama audit pendasaran kami.
- Perhitungan
- NCI's general-population BRCA1/2 prevalence figure (~1 in 400) grounds the body text's "roughly 1 in 400-500" context for how small a share of women carry the pathogenic variant driving the 35x/15x personal-factor multipliers above. Not used in the headline lifetime-incidence calculation, which comes from ACS/SEER.
- Independensi
- NCI germline-genetics fact sheet, independent of the ACS/SEER incidence-and-mortality pipeline used for the headline probability.







